Who we are?
A not-for-profit community interest company with proven expertise for driving change in health policy, based in the UK.
Our aim
Oxford Health Policy Forum (OHPF) calls for policy changes that aim to achieve the best possible outcomes for people living with lifechanging conditions and those who care for them.
Our approach
We bring together a wide range of stakeholders in expert Forums for transparent and constructive dialogue to define the changes needed in our complex healthcare systems to improve life for those impacted by life changing conditions. Our strategy is to ensure uptake of our recommendations through omnichannel dissemination in co-operation with the participants of our Forums.
Brain health – time matters 2024: MS, NMOSD, MOGAD and related conditions
Since our first publication in 2015, care and treatment in neuroimmune conditions have hugely advanced. This new report delves into these advancements and addresses the ongoing needs of those living with these lifelong conditions. MS, NMOSD, and MOGAD are related, chronic, incurable diseases that can severely impact many aspects of life, especially when undiagnosed, misdiagnosed, or not treated early and effectively.
Schizophrenia: Time to Commit to Policy Change 2024
Schizophrenia is recognised as one of the most complex and profound mental health conditions, steeped in both myth and reality. Our report delves into the unique needs of people with schizophrenia, exploring supportive measures and attainable recommendations for change.
"MS Brain Health has changed the way that leading MS neurologists view best practice in MS care"
"Lifestyle recommendations incorporated into newly updated standards for diagnosis and treatment"
"Rapid pathways set up for people newly diagnosed with MS to be seen and treated"
"Updated criteria for reimbursement of DMTs"
"More DMTs available for MS patients"
Brain health – time matters 2024: MS, NMOSD, MOGAD and related conditions
Since our first publication in 2015, care and treatment in neuroimmune conditions have hugely advanced. This new report delves into these advancements and addresses the ongoing needs of those living with these lifelong conditions. MS, NMOSD, and MOGAD are related, chronic, incurable diseases that can severely impact many aspects of life, especially when undiagnosed, misdiagnosed, or not treated early and effectively.
Schizophrenia: Time to Commit to Policy Change 2024
Schizophrenia is recognised as one of the most complex and profound mental health conditions, steeped in both myth and reality. Efforts needs to be multifaceted, including policy development, treatment guidance and scientific innovation, with all stakeholders working together to ensure meaningful progress.
"MS Brain Health has changed the way that leading MS neurologists view best practice in MS care"
"Lifestyle recommendations incorporated into newly updated standards for diagnosis and treatment"
"Rapid pathways set up for people newly diagnosed with MS to be seen and treated"
"Updated criteria for reimbursement of DMTs"
"More DMTs available for MS patients"
The need for continuous policy review
Every year, scientific advances lead to innovations with the potential to transform the lives of patients with life-threatening or debilitating diseases. Gene therapies, vaccines, drugs, devices, apps, nanotechnology and diagnostic tools are all making the seemingly impossible possible.
Adoption of new technologies is increasingly dependent on the broader context in which they will be used. New technologies and their champions must undertake a long journey from evidence to guidelines to adoption; all under considerable budgetary constraints, which can vary in different healthcare systems.
Find out more
If you are interested in working with us to help to improve public health, please get in touch.
